ArticleCell reports2021
Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics.
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2.Virus research · 2023Pooled it
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- Specific Instability of HLA-A*03:01 Expression in HEK-293 Cells.International journal of molecular sciences · 2025Article
- Article
- Machine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines.Nature communications · 2024Article
- Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes.Nature communications · 2024Article
- Development of Detection Antibody Targeting the Linear Epitope in SARS-CoV-2 Nucleocapsid Protein with Ultra-High Sensitivity.International journal of molecular sciences · 2024Article
- Back to the Future: Immune Protection or Enhancement of Future Coronaviruses.Microorganisms · 2024Review
- Thunder-DDA-PASEF enables high-coverage immunopeptidomics and is boosted by MSNature communications · 2024Article
- The HLA-II immunopeptidome of SARS-CoV-2.Cell reports · 2024Article
- FASTMAP-a flexible and scalable immunopeptidomics pipeline for HLA- and antigen-specific T-cell epitope mapping based on artificial antigen-presenting cells.Frontiers in immunology · 2024Article
- A bioinformatic analysis of T-cell epitope diversity in SARS-CoV-2 variants: association with COVID-19 clinical severity in the United States population.Frontiers in immunology · 2024Article
- A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.Molecular therapy. Methods & clinical development · 2023Article
- SARS-CoV-2 Gut-Targeted Epitopes: Sequence Similarity and Cross-Reactivity Join Together for Molecular Mimicry.Biomedicines · 2023Article
- Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T-cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.PLoS pathogens · 2023Article
- Article
- Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues.Nature communications · 2023Article
- HLA Variation and SARS-CoV-2 Specific Antibody Response.Viruses · 2023Review
- HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review.Vaccines · 2023Review
- Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development.Life sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 3 countries.
Funding
Abstract
The human leukocyte antigen (HLA)-bound viral antigens serve as an immunological signature that can be selectively recognized by T cells. As viruses evolve by acquiring mutations, it is essential to identify a range of presented viral antigens. Using HLA peptidomics, we are able to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-derived peptides presented by highly prevalent HLA class I (HLA-I) molecules by using infected cells as well as overexpression of SARS-CoV-2 genes. We find 26 HLA-I peptides and 36 HLA class II (HLA-II) peptides. Among the identified peptides, some are shared between different cells and some are derived from out-of-frame open reading frames (ORFs). Seven of these peptides were previously shown to be immunogenic, and we identify two additional immunoreactive peptides by using HLA multimer staining. These results may aid the development of the next generation of SARS-CoV-2 vaccines based on presented viral-specific antigens that span several of the viral genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.